# OnCo record high-grade-b-cell-lymphoma-myc-bcl2 (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/high-grade-b-cell-lymphoma-myc-bcl2/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "high-grade-b-cell-lymphoma-myc-bcl2" ;
  schema:name "High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma)"@en ;
  schema:alternateName "Double-hit lymphoma"@en, "DHL"@en, "HGBL-MYC/BCL2"@en, "HGBCL-DH-BCL2"@en, "Diffuse large B-cell lymphoma/high grade B-cell lymphoma with MYC and BCL2 rearrangements"@en, "High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements"@en, "Double-hit B-cell lymphoma"@en, "Triple-hit lymphoma"@en ;
  schema:description "An aggressive B-cell lymphoma defined not by how it looks but by two genetic faults in the same cell: a rearrangement of MYC, which drives growth, and one of BCL2, which blocks the cell from dying. It behaves worse than ordinary diffuse large B-cell lymphoma, so finding the rearrangements changes the treatment."@en ;
  schema:url <https://onco.cc/cancers/high-grade-b-cell-lymphoma-myc-bcl2/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma> ;
  schema:citation <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://doi.org/10.1200/JCO.18.01583>, <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq> ;
  onco:tag "heme", "lymphoma", "subtype-page" ;
  onco:related <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/fdg-pet/> ;
  onco:targets <https://onco.cc/pathways/myc/>, <https://onco.cc/targets/bcl2/> ;
  onco:terms <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-indolent-versus-aggressive/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/r-chop/> .